Abstract

The development of safe, effective, and age-appropriate medicinal products for the pediatric population presents a multifaceted challenge arising from immature physiological systems, complex pharmacokinetic variability, swallowing limitations, and historically insufficient clinical data. Children are not small adults; their gastrointestinal pH, enzymatic activity, body composition, and renal function differ substantially from adult benchmarks and evolve continuously from birth through adolescence. This review aims to comprehensively examine current advances in pediatric drug formulation technologies with emphasis on pharmaceutical strategies that improve tolerability, dose accuracy, and therapeutic compliance across all pediatric age groups as classified by ICH E11(R1). Key formulation technologies discussed include age-appropriate liquid and solid oral dosage forms, multiparticulate systems, orodispersible tablets, and modified-release platforms. Emerging innovations such as nanotechnology-based drug delivery, three-dimensional (3D) printing, and personalized medicine approaches are evaluated for their clinical applicability and translational potential. Therapeutic applications encompass the management of infectious diseases, chronic conditions including asthma and epilepsy, and vaccine delivery. Regulatory frameworks from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) are critically reviewed alongside excipient safety considerations unique to pediatric patients. This review underscores the imperative for cross-disciplinary collaboration between formulators, clinicians, and regulatory bodies to accelerate the development of child-friendly medicines that fulfill unmet medical needs while adhering to rigorous safety and quality standards.